Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) FCF Margin (2016 - 2025)

Karyopharm Therapeutics' FCF Margin history spans 14 years, with the latest figure at 34.71% for Q4 2025.

  • For Q4 2025, FCF Margin rose 4963.0% year-over-year to 34.71%; the TTM value through Dec 2025 reached 51.6%, up 3628.0%, while the annual FY2025 figure was 51.6%, 3628.0% up from the prior year.
  • FCF Margin reached 34.71% in Q4 2025 per KPTI's latest filing, down from 13.3% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 20.01% in Q4 2021 to a low of 246.66% in Q2 2021.
  • Average FCF Margin over 5 years is 86.38%, with a median of 79.27% recorded in 2022.
  • Peak YoY movement for FCF Margin: tumbled -12643bps in 2021, then soared 15809bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 20.01% in 2021, then plummeted by -499bps to 79.94% in 2022, then surged by 31bps to 55.07% in 2023, then crashed by -53bps to 84.33% in 2024, then soared by 59bps to 34.71% in 2025.
  • Per Business Quant, the three most recent readings for KPTI's FCF Margin are 34.71% (Q4 2025), 13.3% (Q3 2025), and 49.29% (Q2 2025).